Explore the latest in urologic cancer, including recent screening guidelines and advances in treatment of renal, bladder, and prostate cancers.
This narrative review describes the parallels and differences between prostate cancer and thyroid cancer regarding screening, diagnosis, risk stratification, and considerations for active surveillance.
This randomized clinical trial examines whether patients treated with sunitinib before cytoreductive nephrectomy have better outcomes than patients immediately treated with cytoreductive nephrectomy and then given sunitinib.
In this article, the author discusses his struggles with hope and delusion in his personal experience with renal cell carcinoma.
This Viewpoint addresses whether there is sufficient evidence to support routine use of multiparametric magnetic resonance imaging as an adjunctive test for men with elevated prostate-specific antigen level and considers the practical implications of its widespread implementation.
This Viewpoint assesses the current recommendation of treatment regimens with and without bleomycin for patients with metastatic germ cell tumors of the testis.
This Viewpoint uses results of randomized clinical trials to explore whether the use of abiraterone acetate plus prednisone is a cost-effective and appropriate treatment option for patients with nonmetastatic castration-resistant prostate cancer.
This narrative review discusses the rationale and results of clinical trials in immunotherapy-based combination therapy for patients with advanced renal cell carcinoma.
This cohort study investigates whether treatment of Gleason score 9-10 prostate cancer with radical prostatectomy, adjuvant external beam radiotherapy, and androgen deprivation therapy (termed MaxRP) vs external beam radiotherapy, brachytherapy, and androgen deprivation therapy (termed MaxRT) was associated with prostate cancer–specific mortality and all-cause mortality risk.
This cohort study examines the association of androgen deprivation therapy with dementia in male veterans with prostate cancer who receive definitive radiotherapy.
This cross-sectional analysis compares downstaging, responses, and survival outcomes in patients with muscle-invasive bladder cancer treated with cystectomy who underwent neoadjuvant chemotherapy with gemcitabine with cisplatin, gemcitabine with carboplatin, or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin.
In this narrative medicine essay, a young physician diagnosed with stage III kidney cancer realized with the progressive loss of systems and organs through treatment that he grew to identify with Shel Silverstein’s The Giving Tree, about a tree who gives the boy it loves every part of itself until as a stump all it can offer the now old man is a seat.
This population-based study uses data from the Surveillance, Epidemiology, and End Results (SEER)–Medicare linked database to identify and compare the survival rates and costs attributed to muscle-invasive bladder cancer in older US adults.
This phase 2 clinical trial investigates the safety and efficacy of BIND-014, a docetaxel-containing nanoparticle targeting prostate-specific membrane antigen, for treating patients with metastatic castration-resistant prostate cancer.
This cohort study assesses cystoscopy frequency for patients with low-risk vs high-risk bladder cancer treated at US Veterans Affairs facilities.
This meta-analysis examines the association of Gleason grade with the effectiveness of androgen deprivation therapy with radiotherapy in treating patients with high-risk prostate cancer.
This large cohort study uses the SEER-Medicare database to evaluate the Medicare costs associated with diagnosis and treatment of nonmetastatic prostate cancer in men 70 years or older.
This registry-based cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) database investigates the risk of human papillomavirus (HPV)–associated second primary cancers among survivors of HPV-associated index cancers and tests the hypothesis that the risk of HPV-associated second primary cancer has increased over the last 4 decades.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: